FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Reg. 30 of SEBI LODR, please find enclosed herewith the Transcript of the investors / analysts meet held on August 7, 2023 to discuss the Company''s un-audited financial results for the quarter ended June 30, 2023.
Buy Fortis Healthcare; target of Rs 365: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Fortis Healthcare has recommended buy rating on the stock with a target price of Rs 365 in its research report dated August 07, 2023. FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Reg. 47 of SEBI LODR, please find enclosed copies of newspaper advertisements published on August 9, 2023, inter-alia, intimating completion of the electronic transmission of Postal Ballot Notice along with the Postal Ballot Form to the Members. FORTIS HEALTHCARE LTD. - 532843 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
In compliance of Reg. 30 of SEBI LODR, this is to inform you that the Company has completed dispatch of Postal ballot Notice to its members on August 8, 2023 for seeking their approval on the proposals as detailed in enclosed Postal Ballot Notice. A copy of Postal Ballot Notice and Ballot Form is enclosed. FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the investors / analysts meet held on August 7, 2023 to discuss the Company's un-audited financial results for the quarter ended June 30, 2023 is available on the website of the Company. Q1FY24 Quarterly Result Announced for Fortis Healthcare Ltd.
Fortis Healthcare announced Q1FY24 results: Consolidated revenues for Q1FY24 at Rs 1,657 crore vs Rs 1,488 crore in Q1FY23, a growth of 11.4% Consolidated operating EBITDA at Rs 273 crore versus Rs 251 crore, a growth of 8.7% PBT before exceptional items at Rs 169 crore versus Rs 176 crore PAT before exceptional items at Rs 122 crore versus Rs 134 crore Diagnostics business of the company was renamed “Agilus Diagnostics Limited” Board of Fortis & Agilus has approved for Agilus to initiate an initial public offer process, by way of an offer for sale Company divests its hospital business at Vadapalani, Chennai, to enhance focus on key strategic clusters. Ravi Rajagopal, Chairman, Board of Directors, Fortis Healthcare stated, “For Q1FY24, our consolidated revenues grew 11.4% to Rs 1,657.4 crore while our operating margins stood at 16.5% similar to trailing quarter and marginally lower than Q1FY23. More importantly and signifying our intent to move forward, the quarter witnessed key strategic corporate actions related to both our hospitals and diagnostic business. On the hospital side, our portfolio rationalization strategy gained momentum with the divestment of our loss-making Arcot Road facility in Chennai in July 2023. With an impetus on inorganic growth, we acquired a 350 bedded hospital in Manesar, Gurugram, enabling us to further augment our presence in Delhi-NCR. This we expect to close shortly. Our plans for brownfield bed expansion of close to 1400 beds in the next 2-3 years, increasing our focus on key medical specialties such as oncology and attracting the right clinical talent remain on track. We have initiated the name change of the diagnostics business which is now known as Agilus Diagnostics Limited. I’m also pleased to share that the Board of Fortis and Agilus, today, have granted approval for Agilus to initiate an initial public offer process, by way of an offer for the sale of its equity shares, subject to receipt of requisite approvals, market conditions and other considerations.” Result PDF
Fortis Healthcare falls 2% as net profit declines in Q1
The decline in Q1 bottomline for Fortis Healthcare came on the back of lower occupancy and an unfavourable payor mix. FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Reg. 47 of SEBI LODR, please find enclosed herewith the newspaper advertisements published on August 5, 2023 with respect to un-audited financial results of the Company for the quarter ended on June 30, 2023.
Fortis Healthcare Q1 results: PAT falls 8.6% to Rs 122.5 crore, revenue grows 11.4%
The company's consolidated revenues in the first quarter stood at Rs 1,657 crore against Rs 1,488 crore in the year-ago period, a growth of 11.4 percent. FORTIS HEALTHCARE LTD. - 532843 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Reg. 30 of SEBI LODR, please find enclosed herewith the Press Release and Earnings Presentation for the Quarter ended June 30, 2023